Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash
25 August 2013 | By Amgen
Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash...
List view / Grid view
News
GSK announces phase III study of vercirnon in patients with moderate-to-severe Crohn’s disease did not meet its primary endpoint
23 August 2013 | By GlaxoSmithKline
The first of four Phase III studies, the SHIELD-1 study, investigating vercirnon in adult patients with moderately-to-severely active Crohn’s disease did not achieve the primary endpoint...
Abbott-sponsored session gets to grips with being 60 at FOCUS 2013
21 August 2013 | By kdm communications limited
Corresponding with the 60th Anniversary of the Association for Clinical Biochemistry, Abbott recently hosted an enthusiastically received session at the Annual ACB FOCUS National Meeting held in York, entitled The Diamond Generation; Pathology begins at 60...
Abbott completes acquisition of IDEV Technologies
21 August 2013 | By Abbott
Abbott has completed its acquisition of IDEV Technologies, a privately held company focused on developing next-generation medical devices...
5 steps to complete confidence in your balance purchase
20 August 2013 | By METTLER TOLEDO
Whether you work with simple or complex samples, guaranteeing the correct results is important...
Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)
20 August 2013 | By Novartis
Novartis announced that the US FDA has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM)...
GSK receives EMA approval for new Tyverb® (lapatinib) indication in combination with trastuzumab
19 August 2013 | By Packer Forbes Communications
The EMA has granted an update to the marketing authorisation for Tyverb® (lapatinib) to be used in combination with Herceptin® (trastuzumab)...
Abbott completes acquisition of OptiMedica
19 August 2013 | By Abbott
Abbott has completed its acquisition of OptiMedica Corporation, a privately-held, Silicon Valley-based ophthalmic device company...
Johnson & Johnson completes acquisition of Aragon Pharmaceuticals, Inc.
19 August 2013 | By Johnson & Johnson
Late-stage prostate cancer treatment strengthens oncology pipeline..
Phase III safety and efficacy data of Trajenta® (linagliptin) in elderly people with Type 2 Diabetes published in The Lancet
15 August 2013 | By OgilvyHealthPR London
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo. In addition, the…
Boehringer Ingelheim announces full patient enrolment for two of its pivotal Phase III interferon-free hepatitis C clinical trials
15 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete...
Novartis vaccine Bexsero® approved in Australia to help protect against MenB disease
15 August 2013 | By Novartis
The Australian Therapeutic Goods Administration (TGA) has added Bexsero® to the Australian Register of Therapeutic Goods (ARTG)...
GSK receives marketing authorisation from the European Commission for additional indication: Tyverb™ (lapatinib) in combination with trastuzumab for patients with HER2-positive, HR-negative metastatic breast cancer
14 August 2013 | By GlaxoSmithKline
“Today’s announcement is important for women with this specific type of metastatic breast cancer..."
First half year 2013: Boehringer Ingelheim remains on growth path
14 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim grew further in the first half of 2013, despite difficult overall conditions...
Handheld raman analyzer software improves speed and effectiveness
Pharmaceutical manufacturers and regulatory agencies can now enhance the performance of the Thermo Scientific TruScan RM analyzer by downloading the newest software update. In addition to improved speed, Thermo Fisher Scientific designed the software update to enable users to more effectively develop and validate robust methods for pharmaceutical manufacturing and…
